The Biotechnology Innovation Organization has appointed drug industry executive Michelle McMurry-Heath, a former senior FDA official, as its new president and CEO effective June 1, when current BIO President and CEO Jim Greenwood steps down, the organization announced Thursday (May 14). McMurry-Heath, currently a vice president at Johnson & Johnson, brings a mix of drug industry and regulatory experience to the biotech lobby group as the biotechnology and pharmaceutical industries work to quickly develop treatments, therapies and vaccines to fight...